Visão geral da empresa
A clinical-stage immuno-oncology enterprise, Marker Therapeutics, Inc. focuses on developing and commercializing T cell-based immunotherapies designed to treat hematological malignancies and solid tumor indications within the United States. The firm operates within the Healthcare sector and specifically functions in the Biotechnology industry, positioning itself as a specialized developer of multi antigen recognizing (MAR)-T cell therapy technology. Currently, the company maintains a market capitalization of $22.64M and employs a workforce of 5 individuals, while generating annual revenue of $3.55M based on trailing twelve-month data. These valuation and revenue figures indicate that Marker Therapeutics is a micro-cap entity with a relatively small operational footprint, suggesting that its current financial scale is limited compared to established pharmaceutical peers and that it operates with significant capital constraints typical of early-stage clinical development firms.
Saúde financeira
The company reported revenue of $3.55M over the trailing twelve months, yet incurred a net income loss of $12,163,620, revealing a cost structure where operating expenses significantly outweighed revenue generation, resulting in a net income figure that is more than thirty times the magnitude of total sales. This substantial gap between revenue and net income highlights the heavy burn rate associated with clinical-stage biotechnology activities, where research and development expenditures are the primary driver of cash outflows. The enterprise generated free cash flow of $-8,598,567, indicating a negative cash position that limits immediate financial flexibility and necessitates continuous access to external capital sources to sustain operations. Analyzing the profitability metrics shows a gross margin of -232.7%, an operating margin of -170.7%, and a profit margin of 0.0%, all of which reflect the intense capital intensity of the business model and the inability to generate profit from sales or operations at the current stage of development. On the balance sheet, the company holds cash of $16.07M against zero debt, creating a scenario where total liabilities are absent and the debt-to-equity ratio is effectively N/A due to the lack of debt obligations. The current ratio stands at 8.39, a metric that suggests a highly conservative liquidity position and the ability to meet short-term obligations with substantial ease given the lack of immediate debt service requirements. Furthermore, the Return on Equity is -68.8% and the Return on Assets is -37.8%, metrics that indicate management is currently deploying capital to generate losses rather than returns, a common characteristic for biotechnology firms in the clinical stage but one that underscores the risk profile associated with the firm's capital efficiency.
Avaliação de valorização
Valuation metrics for Marker Therapeutics present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -9.21, implying that earnings-based valuation is not applicable and that the market prices the stock based on future potential rather than current earnings power. The price-to-book ratio is recorded at 1.74, indicating that the market values the company at a premium of 74% over its book value, which may reflect expectations of future asset appreciation or intellectual property value despite current losses. Additionally, the price-to-sales ratio is 6.38, while the EV/EBITDA is N/A, suggesting that investors are relying on revenue multiples rather than earnings or enterprise value multiples to determine fair value in the absence of positive cash generation. Price action analysis reveals a 52-week high of $4.07 and a 52-week low of $0.81, providing a trading range of approximately $3.26, though the specific current price relative to this exact range is not quantified in the provided data, preventing a precise calculation of the percentage distance from the high or low. The stock exhibits a beta of 1.47, which signifies that the security's price volatility is 47% higher than the broader market, indicating that investors should expect amplified price swings during market fluctuations compared to large-cap benchmarks.
Growth & Income
Growth metrics for the company show a revenue growth year-over-year of -51.0%, while earnings growth is N/A due to the company's negative earnings history, implying that the firm is currently contracting in terms of top-line sales rather than expanding its commercial footprint. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment, although the current net loss means the company is burning cash rather than retaining profits for internal growth. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting a strategy focused entirely on clinical progression rather than financial distribution to shareholders. This profile suggests that the company is in a phase of resource depletion to achieve clinical milestones, rather than a stage of mature commercial growth or income generation.